Trial Profile

A Phase 1 Study of CHS-114 in Participants With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CHS 114 (Primary) ; Toripalimab (Primary)
Indications Carcinoma; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man

Most Recent Events

25 Mar 2025 According to a Coherus BioSciences media release,company announced that data from this trial will be presented at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
24 Mar 2025 Planned number of patients changed from 47 to 87.
03 Dec 2024 According to a Coherus BioSciences media release, phase 1 dose escalation is complete. Phase 1 monotherapy biopsy data as well as CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) expected in 1H 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com